Association between chromosome 1p and 19q loss and outcome in pediatric malignant gliomas: Results from the CCG-945 cohort

Pediatric Neurosurgery

Volumn 39, Issue 3, 2003, Pages 114-121

  Pollack, Ian F ^a   Finkelstein, Sydney D ^a   Burnham, Judith ^a   Hamilton, Ronald L ^a   Yates, Allan J ^b   Holmes, Emiko J ^e   Boyett, James M ^c   Finlaye, Jonathan L ^d  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

1p deletions; Anaplastic oligoastrocytoma; Childhood; Glioblastoma; Prognostic factors

Indexed keywords

CISPLATIN; CYTARABINE; DACARBAZINE; HYDROXYUREA; LOMUSTINE; METHYLPREDNISOLONE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ALLELE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ARM; CHROMOSOME DELETION; CHROMOSOME LOSS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; GENE LOCUS; GENOTYPE; GLIOBLASTOMA; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR LOCALIZATION;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD, PRESCHOOL; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; COHORT STUDIES; FEMALE; GENETIC MARKERS; GENOTYPE; GLIOMA; HUMANS; LOSS OF HETEROZYGOSITY; MALE; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 0042743869     PISSN: 10162291     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071647     Document Type: Article

References (40)

1. Bauman GS, Ino Y, Ueki K, et al: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000;48:825-830.
2. Bello MJ, Leone PE, Nebreda P, et al: Allelic status of chromosome 1 in neoplasms of the nervous system. Cancer Genet Cytogenet 1995; 83:160-164.
3. Bredel M, Pollack IF, Hamilton RL, James CD: Epidermal growth factor receptor expression and gene amplification in high-grade nonbrainstem gliomas of childhood. Clin Cancer Res 1999;5:1786-1792.
4. Boyett JB, Yates AJ, Gilles FH, et al: When is a high-grade astrocytoma (HGA) not a HGA? Results of a central review of 226 cases of anaplastic astrocytoma (AA), glioblastoma multiforme (GBM), and other-HGA (Oth-HGA) by five neuropathologists. Proc Am Soc Clin On-col 1998;17:526a.
5. Burger PC, Minn AY, Smith JS, et al: Losses of chromosomes 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 2001;14:842-853.
6. Burger PC, Scheithauer BW, Vogel FS: Surgical Pathology of the Nervous System and Its Coverings, ed 3. New York, Churchill Livingstone, 1991.
7. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-1479.
8. Campbell J, Pollack IF, Martinez AJ, Shultz BL: High-grade astrocytomas in children: Radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery 1996;38:258-264.
9. Cheng Y, Ng H-K, Zhang S-F, et al: Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 1999;30:1284-1290.
10. Collins VP: Progression as exemplified by human astrocytic tumors. Semin Cancer Biol 1999;9:267-276.
11. Duffner PK, Krischer JP, Burger PC, et al: Treatment of infants with malignant gliomas: The Pediatric Oncology Group experience. J Neurooncol 1996;28:245-256.
12. Ellenberg L, McComb JG, Siegel SE, Stowe S: Factors affecting intellectual outcome in pediatric brain tumor patients. Neurosurgery 1987;21:638-644.
13. Finlay JL, Boyett JM, Yates AJ, et al: Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. J Clin Oncol 1995;13:112-123.
14. Finkelstein SD, Sasatomi E, Swalsky PA, Woods J, Lieberman F: Microdissection-based genotyping for optimal molecular diagnosis and prognostication of human gliomas. Neurooncology 2000;2:261.
15. Finkelstein SD, Sayegh R, Christensen S, Swalsky PA: Genotypic classification of colorectal adenocarcinoma. Biologic behavior correlates with K-ras-2 mutation type. Cancer 1993;71:3827-3838.
16. Galanis E, Buckner J, Kimmel D, et al: Gene amplification of a prognostic factor in primary and secondary high-grade malignant gliomas. Int J Oncol 1998;13:717-724.
17. INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 1995;55: 4833-4836.
18. Ino Y, Betensky RA, Zlatescu MC, et al: Molecular subtypes of anaplastic oligodendroglioma: Implications for patient management at diagnosis. Clin Cancer Res 2001;7:839-845.
19. Ino Y, Zlatescu MC, Sasaki H, et al: Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg 2000;92:983-990.
20. Kraus JA, Lamszus K, Glesmann N, et al: Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta Neuropathol 2001;101:311-320.
21. Louis DN: A molecular genetic model of astrocytoma histopathology. Brain Pathol 1997;7: 755-764.
22. Maintz DD, Fiedler K, Koopman J, et al: Molecular genetic evidence for subtypes of oligoastrocytomas. J Neuropathol Exp Neurol 1997; 56:1098-1104.
23. Mason WP, Grovas A, Halpern S, et al: Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 1998;16:210-221.
24. Moore BD 3rd, Ater JL, Copeland DR: Improved neuropsychological outcome in children with brain tumors diagnosed during infancy and treated without cranial irradiation. J Child Neurol 1992;7:281-290.
25. Pollack IF: Current concepts: Brain tumors in children. N Engl J Med 1994;331:1500-1507.
26. Pollack IF, Finkelstein SD, Burnham J, et al: Age and TP53 mutation frequency in childhood malignant gliomas: Results in a multi-institutional cohort. Cancer Res 2001;61: 7404-7407.
27. Pollack IF, Finkelstein SD, Woods J, et al: Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 2002; 346:420-427.
28. Pollack IF, Hamilton RL, Burnham J, et al: Impact of proliferation index on outcome in childhood malignant gliomas: Results in a mul-ti-institutional cohort. Neurosurgery 2002;50: 1238-1244.
29. Pollack IF, Hamilton RL, Finkelstein SD, et al: The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood. Cancer Res 1997; 57:304-309.
30. Radcliffe J, Packer RJ, Atkins TE, et al: Three-and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol 1992; 32:551-554.
31. Raffel C, Frederick L, O'Fallon JR, et al: Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 1999;5: 4085-4090.
32. Sasaki H, Zlatescu MC, Betensky RA, et al: Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade 'oligodendroglioma'. J Neuropathol Exp Neurol 2002;61:58-63.
33. Schmidt MC, Antweiler S, Urban N, et al: Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002;61:321-328.
34. Smith JS, Alderete B, Minn Y, et al: Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999;18:4144-4152.
35. Sposto R, Ertel IJ, Jenkin RDT, et al: The effectiveness of chemotherapy for treatment of high-grade astrocytoma in children: Results of a randomized trial. J Neurooncology 1989;7: 165-177.
36. Sung T, Miller DC, Hayes RL, Alonso M, Yee H, Newcombe EW: Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high-grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol 2000;10:249-259.
37. Sure U, Ruedi D, Tachibana O, Yonekawa Y, Ohgaki H, Kleihues P, Hegi ME: Determination of p53 mutations, EGFR overexpression, and low of p16 expression in pediatric glioblastomas. J Neuropathol Exp Neurol 1997;56: 782-789.
38. von Deimling A, von Ammon K, Schoenfeld D, Weistler OD, Seizinger BR, Louis DN: Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3: 19-26.
39. Watanabe K, Tachibana O, Sato K, Yonekawa Y, Kleihues P, Ohgaki H: Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6: 217-224.
40. Wooten EC, Fults D, Duggirala R, et al: A study of loss of heterozygosity at 70 loci in anaplastic astrocytoma and glioblastoma multi-forme with implications for tumor evolution. Neurooncol 1999;1:169-176.